KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Other Accumulated Expenses (2018 - 2025)

Twist Bioscience (TWST) has disclosed Other Accumulated Expenses for 8 consecutive years, with $13.5 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 156.89% to $13.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.5 million through Dec 2025, up 156.89% year-over-year, with the annual reading at $12.1 million for FY2025, 108.85% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $13.5 million at Twist Bioscience, up from $12.1 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $20.1 million in Q2 2022, with the low at $2.9 million in Q4 2021.
  • Average Other Accumulated Expenses over 5 years is $9.9 million, with a median of $9.4 million recorded in 2021.
  • The sharpest move saw Other Accumulated Expenses surged 7713.46% in 2021, then crashed 60.47% in 2023.
  • Over 5 years, Other Accumulated Expenses stood at $2.9 million in 2021, then soared by 447.47% to $15.8 million in 2022, then tumbled by 59.44% to $6.4 million in 2023, then decreased by 18.32% to $5.2 million in 2024, then surged by 156.89% to $13.5 million in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $13.5 million, $12.1 million, and $11.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.